US and China Jiahe (02453) Fa Yingxi expect gross profit of about 63 million yuan to 83 million yuan for the first half of the year, an increase of about 16,349% to 21,571% year-on-year

According to the Zhitong Finance App, the US and China Jiahe (02453) announced that the Group is expected to achieve revenue of about RMB 260 million to RMB 280 million in the first half of 2026, while the six months ending June 30, 2025 will record revenue of about RMB 200.9 million, an increase of about 29% to 39%; the first half of 2026 will achieve gross profit of about RMB 63 million to RMB 83 million, while the six months ended June 30, 2025 will record gross profit of about RMB 380,000, an increase of about 16,349% to 21,571% year on year.

Revenue increased further year-on-year in the first half of 2026, and gross profit increased sharply, mainly due to increased revenue from the proton therapy business of Guangzhou Taihe Cancer Hospital Co., Ltd., a subsidiary of the Group. The total number of patients served exceeded 1,000, and the number of patients treated in a single day exceeded 100. In the future, the Group will continue to optimize service processes, improve diagnosis and treatment efficiency, and strive to provide high-quality medical services to more cancer patients.